New study finds that experimental drug sparsentan is an effective treatment for the rare kidney disease focal segmental glomerulosclerosis, which currently has no FDA-approved therapies.
New study finds that experimental drug sparsentan is an effective treatment for the rare kidney disease focal segmental glomerulosclerosis, which currently has no FDA-approved therapies.